{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:33Z","timestamp":1761059193525},"reference-count":0,"publisher":"Canadian Science Publishing","issue":"4","license":[{"start":{"date-parts":[[1983,4,1]],"date-time":"1983-04-01T00:00:00Z","timestamp":418003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[1983,4,1]]},"abstract":"<jats:p> A recovery study was conducted to determine whether phenytoin (DPH), like the barbiturates, is metabolized via the recently discovered N-glucosidation pathway. Virtually 100% of the ingested <jats:sup>14<\/jats:sup>C-labelled doses in two subjects could be accounted for in the excreta within 5 days, with 35% in feces and 65% in urine. Radioactivity in the urine was entirely due to free and conjugated 5-(4-hydroxy-phenyl)-5-phenylhydantoin (p-HPPH) and the dihydrodiol, and that in the feces mostly due to the unmetabolized drug. There was no indication of phenytoin N-glucoside being excreted in either the urine or feces of either subject, although one of the subjects was known to possess a particularly strong N-glucosidation capacity for barbiturates. The other subject was a poor metabolizer of debrisoquine and sparteine. Nevertheless, the DPH disappearance from serum and the DPH metabolite excretion in urine were virtually alike in these two subjects, indicating that the debrisoquine 4-hydroxylating and DPH hydroxylating capacities may be separable entities. <\/jats:p>","DOI":"10.1139\/y83-061","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T08:52:38Z","timestamp":1303635158000},"page":"403-407","source":"Crossref","is-referenced-by-count":8,"title":["The fate of orally administered [4-<sup>l4<\/sup>C]phenytoin in two healthy male volunteers"],"prefix":"10.1139","volume":"61","author":[{"given":"D.","family":"Kadar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. D.","family":"Fecycz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Kalow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/y83-061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T16:24:12Z","timestamp":1578241452000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/y83-061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,4,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1983,4,1]]}},"alternative-id":["10.1139\/y83-061"],"URL":"https:\/\/doi.org\/10.1139\/y83-061","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,4,1]]}}}